Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 6Lymphoma, T-Cell, Cutaneous 3Carcinoma, Renal Cell 3Sezary Syndrome 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

fludarabine 2ripretinib 1pembrolizumab 1fludarabine phosphate 1bintrafusp alfa protein, human 1Therapeutics 1Tetrahydrouridine 1Stem Cell Transplantation 1Sirolimus 1Psychiatric Rehabilitation 1Mesna 1Melphalan 1Decitabine 1Cyclophosphamide 1Celecoxib 1Busulfan 1Azacitidine 1Amplified Fragment Length Polymorphism Analysis 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × Azacitidine × Dermatologic × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡